Skip to content 
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. more
| Time Frame | CRSP | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 0.73% | -0.26% | 0.42% |
| 1-Month Return | 1.62% | 1.2% | 1.02% |
| 3-Month Return | 8.46% | 3.86% | 4.93% |
| 6-Month Return | 0.73% | 14.37% | 7.32% |
| 1-Year Return | 6.01% | 6.82% | 12.16% |
| 3-Year Return | 14.65% | 20.71% | 71.63% |
| 5-Year Return | -61.42% | 37.78% | 76.95% |
| 10-Year Return | 279.42% | 135.17% | 252.5% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 913.08M | 436.00K | 370.00M | 35.00M | 3.51M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.05,"profit":true},{"date":"2023-12-31","value":40.52,"profit":true},{"date":"2024-12-31","value":3.83,"profit":true},{"date":"2025-12-31","value":0.38,"profit":true}] |
| Cost of Revenue | 101.18M | 110.25M | 130.25M | 110.25M | 232.96M | [{"date":"2021-12-31","value":43.43,"profit":true},{"date":"2022-12-31","value":47.33,"profit":true},{"date":"2023-12-31","value":55.91,"profit":true},{"date":"2024-12-31","value":47.33,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | 913.08M | (109.81M) | 239.75M | (75.25M) | (229.45M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-12.03,"profit":false},{"date":"2023-12-31","value":26.26,"profit":true},{"date":"2024-12-31","value":-8.24,"profit":false},{"date":"2025-12-31","value":-25.13,"profit":false}] |
| Gross Margin | 100.00% | (25186.70%) | 64.80% | (215.00%) | (6537.01%) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25186.7,"profit":false},{"date":"2023-12-31","value":64.8,"profit":true},{"date":"2024-12-31","value":-215,"profit":false},{"date":"2025-12-31","value":-6537.01,"profit":false}] |
| Operating Expenses | 539.55M | 563.35M | 462.29M | 391.32M | 338.87M | [{"date":"2021-12-31","value":95.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.06,"profit":true},{"date":"2024-12-31","value":69.46,"profit":true},{"date":"2025-12-31","value":60.15,"profit":true}] |
| Operating Income | 373.53M | (673.16M) | (222.54M) | (466.57M) | (568.32M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-180.22,"profit":false},{"date":"2023-12-31","value":-59.58,"profit":false},{"date":"2024-12-31","value":-124.91,"profit":false},{"date":"2025-12-31","value":-152.15,"profit":false}] |
| Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | 379.53M | (650.50M) | (150.72M) | (362.67M) | (577.97M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-171.4,"profit":false},{"date":"2023-12-31","value":-39.71,"profit":false},{"date":"2024-12-31","value":-95.56,"profit":false},{"date":"2025-12-31","value":-152.28,"profit":false}] |
| Income Taxes | 1.87M | (325.00K) | 2.89M | 3.59M | 3.63M | [{"date":"2021-12-31","value":51.46,"profit":true},{"date":"2022-12-31","value":-8.94,"profit":false},{"date":"2023-12-31","value":79.47,"profit":true},{"date":"2024-12-31","value":98.71,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income After Taxes | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | 377.66M | (650.17M) | (153.61M) | (366.25M) | (581.60M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-172.16,"profit":false},{"date":"2023-12-31","value":-40.67,"profit":false},{"date":"2024-12-31","value":-96.98,"profit":false},{"date":"2025-12-31","value":-154,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 377.66M | (650.17M) | (153.61M) | (366.25M) | (581.60M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-172.16,"profit":false},{"date":"2023-12-31","value":-40.67,"profit":false},{"date":"2024-12-31","value":-96.98,"profit":false},{"date":"2025-12-31","value":-154,"profit":false}] |
| EPS (Diluted) | 4.42 | (8.37) | (1.96) | (4.37) | (5.41) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-189.37,"profit":false},{"date":"2023-12-31","value":-44.34,"profit":false},{"date":"2024-12-31","value":-98.87,"profit":false},{"date":"2025-12-31","value":-122.4,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| CRSP | |
|---|---|
| Cash Ratio | 13.25 |
| Current Ratio | 13.25 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CRSP | |
|---|---|
| ROA (LTM) | -15.76% |
| ROE (LTM) | -30.18% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CRSP | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.15 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CRSP | |
|---|---|
| Trailing PE | NM |
| Forward PE | 23.36 |
| P/S (TTM) | 1463.57 |
| P/B | 2.65 |
| Price/FCF | NM |
| EV/R | 146.21 |
| EV/Ebitda | 14.16 |
| PEG | NM |
Crispr Therapeutics AG (CRSP) share price today is $53.46
Yes, Indians can buy shares of Crispr Therapeutics AG (CRSP) on Vested. To buy
Yes, you can purchase fractional shares of Crispr Therapeutics AG (CRSP) via the Vested app. You can start investing in Crispr Therapeutics AG (CRSP) with a minimum investment of $1.
You can invest in shares of Crispr Therapeutics AG (CRSP) via Vested in three simple steps:
The 52-week high price of Crispr Therapeutics AG (CRSP) is $78.48. The 52-week low price of Crispr Therapeutics AG (CRSP) is $30.04.
The price-to-earnings (P/E) ratio of Crispr Therapeutics AG (CRSP) is
The price-to-book (P/B) ratio of Crispr Therapeutics AG (CRSP) is 2.65
The dividend yield of Crispr Therapeutics AG (CRSP) is 0.00%
The market capitalization of Crispr Therapeutics AG (CRSP) is $5.24B
The stock symbol (or ticker) of Crispr Therapeutics AG is CRSP
Consider the share price of Crispr Therapeutics AG as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Crispr Therapeutics AG has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Crispr Therapeutics AG shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Crispr Therapeutics AG stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Crispr Therapeutics AG and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Crispr Therapeutics AG stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
